Correlation between NT-proBNP, hs-CRP, left atrium diameter and chronic heart failure concurrent with atrial fibrillation

doi:10.3969/j.issn.1004-583X.2021.05.005

Abstract

Abstract:

Objective To analyze the correlation between N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), left atrium diameter (LAD) and chronic heart failure (CHF) concurrent with atrial fibrillation. Methods A total of 287 CHF patients treated in our hospital from September 2019 to September 2020 were selected, 91 patients with atrial fibrillation were divided into the observation group and 196 patients without atrial fibrillation into in the control group. The difference of general information, blood glucose, blood lipid, uric acid, creatinine, NT-proBNP, hs-CRP and echocardiogram indexes in the two groups were analyzed, and the risk factors of CHF concurrent with atrial fibrillation were analyzed by Logistic regression. Results The course of disease, proportion of patients with New York Heart Association(NYHA) grade IV, uric acid, creatinine, NT-proBNP, hs-CRP, as well as LAD in the observation group were higher than in the control group(P<0.01). Logistic regression analysis showed that the course of disease (OR=1.638), cardiac function class (OR=2.242), NT-proBNP (OR=2.863), hs-CRP (OR=2.341), LAD(OR=3.671) were the main influencing factors of CHF concurrent with atrial fibrillation (P<0.05). Conclusion Long course of disease, IV in NYHA grade, the levels of NT-proBNP, hs-CRP and LAD increase added the risk of CHF concurrent with atrial fibrillation of patients. For CHF patients, targeted intervention should be strengthened to reduce the incidence of atrial fibrillation.

Key words: heart failure, inflammatory factors, atrial fibrillation, left atrium diameter, heart function

CLC Number:

Zhao Meili, Xiao Liyuan, Liu Lin, Kang Chao, Zhang Qiuxiang. Correlation between NT-proBNP, hs-CRP, left atrium diameter and chronic heart failure concurrent with atrial fibrillation[J]. Clinical Focus, 2021, 36(5): 412-415.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.05.005

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I5/412

Figures/Tables 5

References 20

[1]	Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals[J]. Lancet, 2018, 391(10120):572-580. doi: 10.1016/S0140-6736(17)32520-5 URL
[2]	Karnik AA, Gopal DM, Ko D, et al. Epidemiology of atrial fibrillation and heart failure: A growing and important problem[J]. Cardiol Clin, 2019, 37(2):119-129. doi: S0733-8651(19)30001-3 pmid: 30926013
[3]	Mene-Afejuku TO, López PD, Akinlonu A, et al. Atrial fibrillation in patients with heart failure: Current state and future directions[J]. Am J Cardiovasc Drugs, 2018, 18(5):347-360. doi: 10.1007/s40256-018-0276-1 URL
[4]	中华医学会心血管病分会. 慢性心力衰竭诊断治疗指南[J]. 中华心血管病杂志, 2007; 35(12):1076-95.
[5]	January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons[J]. Circulation, 2019, 140(2):e125-e151. doi: 10.1161/CIR.0000000000000665
[6]	Ambrosy AP, Bhatt AS, Gallup D, et al. Trajectory of congestion metrics by ejection fraction in patients with acute heart failure(from the Heart Failure Network)[J]. Am J Cardiol, 2017, 120(1):98-105. doi: S0002-9149(17)30620-3 pmid: 28479167
[7]	闫伟, 何昆仑. 老年慢性心力衰竭住院患者的临床特点和预后分析[J]. 中华老年心脑血管病杂志, 2020, 22(7):702-706.
[8]	Darche FF, Baumg-Rtner C, Biener M, et al. Comparative accumcy of NT-proBNP and MR-proANP for the diagnosis of acute heart failure in dyspnoeic patients[J]. ESC Heart Fail, 2017, 4(3):232-240.
[9]	高莉. 慢性心力衰竭合并心房颤动患者心脏结构功能与血浆脑钠肽水平变化及临床意义分析[J]. 山西医药杂志, 2019, 48(11):1319-1321.
[10]	吕海珍, 吕云, 周荣等. 血清HCY、sST2和NT-proBNP联合检测对慢性心力衰竭诊断及心功能评价的价值[J]. 中国实验诊断学, 2019, 23(6):1002-1006.
[11]	高晓丽, 顾爱峰, 谢明, 等. 基于NT-proBNP目标导向的治疗方案对慢性心力衰竭患者近期预后及再住院的影响[J]. 现代中西医结合杂志, 2018, 27(7):707-710.
[12]	乔香瑞, 刘军辉, 花蕊, 等. 循环单核细胞和血浆中GDF-15和NT-proBNP对慢性心力衰竭的诊断及心血管事件的预测价值[J]. 南方医科大学学报, 2019, 39(11):1273-1279.
[13]	Kim KE, Heo JS, Han S, et al. Blood concentrations of lipopolysaccharide-binding protein, high-sensitivity C-reactive protein, tumor necrosis factor-α, and Interleukin-6 in relation to insulin resistance in young adolescents[J]. Clin Chim Acta, 2018, 486:115-121. doi: 10.1016/j.cca.2018.07.042 URL
[14]	Karam BS, Chavez-Moreno A, Koh W, et al. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes[J]. Cardiovasc Diabetol, 2017, 16(1):120. doi: 10.1186/s12933-017-0604-9 URL
[15]	Dawood FZ, Judd S, Howard VJ, et al. High-sensitivity c-reactive protein and risk of stroke in atrial fibrillation(from the reasons for geographic and racial differences in stroke study)[J]. Am J Cardiol, 2016, 118(12):1826-1830. doi: S0002-9149(16)31476-X pmid: 27712649
[16]	林育辉, 戴文军, 何晓青, 等. 慢性心力衰竭合并心房颤动患者心型脂肪酸结合蛋白、超敏C反应蛋白及同型半胱氨酸水平的变化[J]. 实用医学杂志, 2018, 34(8):1327-1329, 1334.
[17]	韩霜, 李沁, 郑在英, 等. 老年慢性心力衰竭患者心房颤动影响因素[J]. 中国老年学杂志, 2020, 40(2):244-246.
[18]	Li N, Dobrev D. Targeting atrial fibrillation promoting atrial structural remodeling:Is this a viable strategy in patients with heart failure?[J]. Naunyn Schmiedebergs Arch Pharmacol, 2018, 391(3):231-233. doi: 10.1007/s00210-018-1463-y URL
[19]	孙慧, 田峰, 杨林风等. 慢性心力衰竭患者血清sSema4D、MMP-14水平变化及其与心室重构的关系[J]. 山东医药, 2019, 59(5):59-61.
[20]	纪禹同, 黎蔚华, 冯国飞, 等. 左心房内径与高龄心房颤动合并缺血性卒中的相关性分析[J]. 中国心血管病研究, 2020, 18(1):21-24, 67.

组别		例数		性别[例(%)]				年龄 (岁)		BMI (kg/m²)		病程 (月)
组别		例数		男		女		年龄 (岁)		BMI (kg/m²)		病程 (月)
观察组		91		55(60.44)		36(39.56)		58.27±7.92		23.77±3.25		31.45±9.72
对照组		196		118(60.20)		78(39.80)		56.82±6.75		23.95±3.12		23.14±10.37
χ²/t值				0.001				1.601		0.449		6.442
P值				0.970				0.111		0.654		<0.01
组别	例数		NYHA心功能分级[例(%)]					合并症[例(%)]			饮酒史 [例(%)]		吸烟史 [例(%)]
组别	例数		Ⅱ级		Ⅲ级		Ⅳ级	糖尿病	高血压		饮酒史 [例(%)]		吸烟史 [例(%)]
观察组	91		8(8.79)		57(62.64)		26(28.57)	37(40.66)	34(37.36)		17(18.68)		41(45.05)
对照组	196		31(15.82)		136(69.39)		29(14.80)	78(39.80)	77(39.29)		38(19.39)		79(40.31)
χ²/t值			2.612		1.286		7.613	0.019	0.097		0.020		0.576
P值			0.106		0.257		0.006	0.890	0.756		0.887		0.448

组别		例数		性别[例(%)]				年龄 (岁)		BMI (kg/m²)		病程 (月)
组别		例数		男		女		年龄 (岁)		BMI (kg/m²)		病程 (月)
观察组		91		55(60.44)		36(39.56)		58.27±7.92		23.77±3.25		31.45±9.72
对照组		196		118(60.20)		78(39.80)		56.82±6.75		23.95±3.12		23.14±10.37
χ²/t值				0.001				1.601		0.449		6.442
P值				0.970				0.111		0.654		<0.01
组别	例数		NYHA心功能分级[例(%)]					合并症[例(%)]			饮酒史 [例(%)]		吸烟史 [例(%)]
组别	例数		Ⅱ级		Ⅲ级		Ⅳ级	糖尿病	高血压		饮酒史 [例(%)]		吸烟史 [例(%)]
观察组	91		8(8.79)		57(62.64)		26(28.57)	37(40.66)	34(37.36)		17(18.68)		41(45.05)
对照组	196		31(15.82)		136(69.39)		29(14.80)	78(39.80)	77(39.29)		38(19.39)		79(40.31)
χ²/t值			2.612		1.286		7.613	0.019	0.097		0.020		0.576
P值			0.106		0.257		0.006	0.890	0.756		0.887		0.448

组别	例数	FBG (mmol/L)	TC (mmol/L)	TG (mmol/L)	HDL-C (mmol/L)	LDL-C (mmol/L)	UA (μmol/L)	Cr (μmol/L)
观察组	91	6.73±1.13	4.67±1.16	1.78±0.89	1.12±0.59	3.41±0.52	435.82±86.28	123.84±29.45
对照组	196	6.54±1.05	4.59±0.97	1.94±0.84	1.14±0.46	3.34±0.48	391.47±91.53	112.43±25.73
t值		1.392	0.610	1.473	0.312	1.119	3.889	3.336
P值		0.165	0.542	0.142	0.755	0.264	<0.01	0.001

组别	例数	FBG (mmol/L)	TC (mmol/L)	TG (mmol/L)	HDL-C (mmol/L)	LDL-C (mmol/L)	UA (μmol/L)	Cr (μmol/L)
观察组	91	6.73±1.13	4.67±1.16	1.78±0.89	1.12±0.59	3.41±0.52	435.82±86.28	123.84±29.45
对照组	196	6.54±1.05	4.59±0.97	1.94±0.84	1.14±0.46	3.34±0.48	391.47±91.53	112.43±25.73
t值		1.392	0.610	1.473	0.312	1.119	3.889	3.336
P值		0.165	0.542	0.142	0.755	0.264	<0.01	0.001

组别	例数	NT-proBNP(ng/L)	hs-CRP(mg/L)
观察组	91	258.27±13.64	31.48±3.58
对照组	196	179.34±12.36	19.74±3.22
t值		48.695	27.727
P值		<0.01	<0.01